AzurRx BioPharma to Present at Investor Summit Group’s Q2 Virtual Investor Summit (May 17)
11 May 2021 - 9:30PM
AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”),
a clinical stage biopharmaceutical company specializing in the
development of targeted, non-systemic therapies for
gastrointestinal (GI) diseases, today announced that James
Sapirstein, AzurRx President, CEO and Chairman, will present at
Investor Summit Group’s Q2 Virtual Investor Summit taking place May
17-18, 2021.
During his live virtual presentation on Monday, May 17, 2021 at
9:30 a.m. EDT, Mr. Sapirstein will provide an overview of AzurRx’s
business and clinical development programs and discuss anticipated
2021 and early 2022 milestones. Additionally, Mr. Sapirstein and
members of the AzurRx management team will be participating in
virtual one-on-one meetings with registered investors.
Details of the presentation are as follows:
Event: |
Investor Summit Group’s Q2 Virtual Summit |
Date: |
Monday, May 17, 2021 |
Time: |
9:30 a.m., EDT |
Registration:Presentation: |
https://investorsummitgroup.com/register/https://zoom.us/webinar/register/WN_GvA0wYzFTm6gUl0u2xZSqg |
About AzurRx BioPharma, Inc.AzurRx BioPharma,
Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company
specializing in the development of targeted, non-systemic therapies
for gastrointestinal (GI) diseases. The Company has a pipeline of
three gut-restricted GI assets. The lead therapeutic candidate is
MS1819, a recombinant lipase for the treatment of exocrine
pancreatic insufficiency (EPI) in patients with cystic fibrosis and
chronic pancreatitis, currently in two Phase 2 clinical trials.
AzurRx is launching two clinical programs using proprietary
formulations of niclosamide, a pro-inflammatory pathway inhibitor,
FW-420, for grade 1 Immune Checkpoint Inhibitor Colitis and
diarrhea in oncology patients and FW-1022, for COVID-19
gastrointestinal infections. The Company is headquartered in Delray
Beach, Florida with clinical operations in Hayward, California. For
more information, visit www.azurrx.com.
Forward-Looking StatementThis press release may
contain certain statements relating to future results which are
forward-looking statements. It is possible that the Company’s
actual results and financial condition may differ, possibly
materially, from the anticipated results and financial condition
indicated in these forward-looking statements, depending on factors
including whether results obtained in preclinical and nonclinical
studies and clinical trials will be indicative of results obtained
in future clinical trials; whether preliminary or interim results
from a clinical trial will be indicative of the final results of
the trial; and the impact of the coronavirus (COVID-19) pandemic on
the Company’s operations and current and planned clinical trials,
including potential delays in clinical trial recruitment and
participation. Additional information concerning the Company and
its business, including a discussion of factors that could
materially affect the Company’s financial results are contained in
the Company’s Annual Report on Form 10-K for the year ended
December 31, 2019 under the heading “Risk Factors,” as well as the
Company’s subsequent filings with the Securities and Exchange
Commission. All forward-looking statements included in this press
release are made only as of the date of this press release, and we
do not undertake any obligation to publicly update or correct any
forward-looking statements to reflect events or circumstances that
subsequently occur or of which we hereafter become aware.
For more information:AzurRx BioPharma, Inc.1615
South Congress AvenueSuite 103Delray Beach, Florida 33445Phone:
(646) 699-7855info@azurrx.com
Media contact:Tiberend Strategic Advisors,
Inc.Johanna Bennett/Ingrid Mezo(212) 375-2665/(646)
604-5150jbennett@tiberend.com/imezo@tiberend.com
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Apr 2024 to May 2024
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From May 2023 to May 2024